Day: September 19, 2021

Storage Tank Market worth USD 17.72 billion by 2028, registering a CAGR of 4.25% - Report by Market Research Future (MRFR)

Storage Tank Market worth USD 17.72 billion by 2028, registering a CAGR of 4.25% – Report by Market Research Future (MRFR)

New York, Sept. 20, 2021 (GLOBE NEWSWIRE) — Storage Tank Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Storage Tank Market Research Report: Information, by Installation Type (Aboveground Storage Tanks (ASTs) and Underground Storage Tanks (USTs)), Product (Hazardous and Non-Hazardous), Material (Steel, Concrete, Polyethylene and others), Industry Vertical (Oil and Gas, Chemical, Water, Food and Beverage and others) and Region (North America, Europe, Asia–Pacific and RoW) – Forecast till 2028” the market is projected to be worth USD 17.72 billion by 2028, registering a CAGR of 4.25% during the forecast period (2021 – 2028)., The market was valued at USD 13.12 billion in 2021. Competitive Analysis List of the Key Companies Profiled in the Storage Tank Market Report are...

Continue reading

Solar Thermal Collectors Market worth USD 44.87 billion by 2028, registering a CAGR of 8.15% - Report by Market Research Future (MRFR)

Solar Thermal Collectors Market worth USD 44.87 billion by 2028, registering a CAGR of 8.15% – Report by Market Research Future (MRFR)

New York, Sept. 20, 2021 (GLOBE NEWSWIRE) — Solar Thermal Collectors Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Solar Thermal Collectors Market Research Report by Product Type (Concentrating, Non-concentrating), Application (Residential, Industrial, Commercial) and Region-Global Forecast to 2028” the market is projected to be worth USD 44.87 billion by 2028, registering a CAGR of 8.15% during the forecast period (2021 – 2028). Competitive Analysis Key players profiled in the solar thermal collector market are – TVP Solar (Switzerland) Alternate Energy Technologies LLC. (US) Ouraset(Turkey) Greenonetec Solarindustrie GMBH (Austria) SunEarth (California) Sunerg Solar s.r.l. (Italy) Absolicon Solar Collector AB (Sweden) Solimpeks (Turkey) HTP Comfort Solutions...

Continue reading

Passive Temperature Controlled Packaging Market worth USD 13.85 billion by 2028, registering a CAGR of 9.65% - Report by Market Research Future (MRFR)

Passive Temperature Controlled Packaging Market worth USD 13.85 billion by 2028, registering a CAGR of 9.65% – Report by Market Research Future (MRFR)

New York, Sept. 20, 2021 (GLOBE NEWSWIRE) — Passive Temperature Controlled Packaging Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Passive Temperature Controlled Packaging Market Research Report, Type, Application and Region – Forecast till 2028” the market to be worth USD 13.85 billion by 2028, registering a CAGR of 9.65% during the forecast period (2021 – 2028). Competitive Landscape Players leading the global Passive Temperature Controlled Packaging Market profiled include – Sonoco Products Company (US) Pelican BioThermal LLC (US) Cold Chain Technologies Inc.(US) AmerisourceBergen Corporation(US) FedEx Corporation (US) Deutsche Post AG (Germany) Softbox (UK) Intelsius (UK) Sofrigam SA Ltd. (US) OMEGA Engineering (US) ACH Foam Technologies (US) WIKA Alexander Wiegand...

Continue reading

Laredo Petroleum Announces Expansion of Oil-Weighted Western Glasscock Leasehold

Laredo Petroleum Announces Expansion of Oil-Weighted Western Glasscock Leasehold

TULSA, OK, Sept. 19, 2021 (GLOBE NEWSWIRE) — Laredo Petroleum, Inc. (NYSE: LPI) (“Laredo” or the “Company”) today announced the signing of a purchase and sale agreement to acquire approximately 20,000 net acres in western Glasscock County from Pioneer Natural Resources Company (NYSE: PXD) (“Pioneer”) for approximately $230 million, subject to customary closing price adjustments. This is Laredo’s second significant acquisition in 2021, as the Company continues to execute its transformational strategy and expand its high-margin inventory. The leasehold to be acquired is directly adjacent to Laredo’s existing western Glasscock leasehold, expanding its oil-weighted core development area in the prolific Midland Basin. The transaction is expected to close in October 2021. Highlights: Increases high-margin,...

Continue reading

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

As a general screening for all-comers (i.e. COVID-19 symptomatic and asymptomatic populations), COVISTIX (n=783) has an 81% sensitivity vs. 62% (n=2202) sensitivity by globally leading Panbio rapid antigen test. SAN DIEGO, Sept. 19, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN (The Institute of National Genomics Medicine, Mexico). Detailed results can be found at: https://www.medrxiv.org/content/10.1101/2021.09.10.21263410v1 “Analytical performances of the COVISTIX™ and Panbio™ antigen rapid tests for SARS-CoV-2...

Continue reading

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC Phase 3 trial met its primary and key secondary endpoints Libtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with chemotherapy Trial enrolled patients with varied baseline characteristics, including squamous and non-squamous histologies and all PD-L1 expression levels; 84% had an ECOG 1 performance status (reduced daily functioning) PARIS and TARRYTOWN, N.Y. – September 19, 2021 – Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.’s Libtayo® (cemiplimab) combination treatment were presented today during a late-breaking...

Continue reading

Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

Media Release Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging, Durable Anti-Tumor Activity in Previously Treated Patients COPENHAGEN, Denmark, and BOTHELL, Wash.; September 19, 2021 – Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today presented interim data from two cohorts of the Phase 1b/2 innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 as part of a featured mini oral presentation. Initial results from these two dose expansion cohorts of the study showed encouraging and durable anti-tumor activity with tisotumab vedotin in combination with...

Continue reading

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs. placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004)2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with different endocrine therapy partners, regardless of menopausal status or line of therapy2-4   MONALEESA-2 OS data to be presented at ESMO Congress 2021 as a late-breaker in an oral session  The digital press release with multimedia content can be accessed here: Basel, September 19, 2021 — Novartis...

Continue reading

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for etesevimab (JS016/LY-CoV016) 1,400 mg and bamlanivimab (LY-CoV555) 700 mg administered together (the “Therapy”) to include post-exposure prophylaxis in certain individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in institutional settings, including nursing homes...

Continue reading